Japanese firms Astellas Pharma Inc., Nitto Denko Corporation, and M. Heart Co., have announced that the three companies have concluded a memorandum of understanding (MoU) concerning an ECG testing service.
Japanese firms Astellas Pharma Inc., Nitto Denko Corporation, and M. Heart Co., have announced that the three companies have concluded a memorandum of understanding (MoU) concerning an ECG testing service.
Bristol-Myers Squibb Company ( BMY ) announced that ONO-4538-12, a Phase 3 clinical trial evaluating the efficacy and safety of Opdivo (nivolumab) in patients with unresectable advanced or recurrent gastric cancer refractory to, or intolerant of, standard therapy, met its primary endpoint of overall survival. Ono Pharma of Japan, Bristol-Myers Squibb's development partner for Opdivo, conducted the ONO-4538-12 trial. The companies will work with investigators on the future presentation of the study results.
Under the deal, BMS gains exclusive worldwide rights to Nitto’s investigational siRNA molecules targeting heat shock protein 47 (HSP47) in vitamin A-containing formulations--which includes Nitto’s lead asset ND-L02-s0201, currently in Phase Ib for advanced liver fibrosis due to nonalcoholic fatty liver disease, or NASH, as well as scarring due to hep C infection.